Orasis Pharmaceuticals Expands Qlosi Access with New Starter Packs Following Strong Market Adoption
核心洞察
Orasis Pharmaceuticals (搜索) has launched Starter Packs for Qlosi (搜索) (pilocarpine hydrochloride ophthalmic solution) 0.4% to broaden patient access and provide eye care professionals with hands-on experience.
Since its U.S. launch in April 2025, Qlosi (搜索) has achieved strong market adoption with thousands of prescribing eye care professionals and refill rates exceeding expectations.
Each Starter Pack contains 10 vials providing five days of treatment, along with patient tracking tools, shipped directly to prescribing eye care professionals.
Orasis Pharmaceuticals (搜索) has announced the availability of Starter Packs for Qlosi (搜索) (pilocarpine hydrochloride ophthalmic solution) 0.4%, marking the next phase of the presbyopia (搜索) treatment's commercial expansion following strong market adoption since its U.S. launch in April 2025.
The company reports that thousands of eye care professionals are now prescribing Qlosi (搜索), with refill rates exceeding expectations and no serious adverse events reported since launch according to FDA Adverse Event Reporting System data. The direct-to-consumer campaigns have generated significant engagement, with over 1 million clicks to learn about the treatment.
Commercial Strategy and Market Response
"Orasis remains deeply committed to redefining how people think about presbyopia (搜索) treatment – moving beyond the limitations of reading glasses," said Elad Kedar, Chief Executive Officer of Orasis Pharmaceuticals (搜索). "This year alone, our targeted, direct-to-consumer (DTC) campaigns have led to a high level of engagement with over 1 million clicks to learn about Qlosi (搜索). With the introduction of Qlosi Starter Packs, we're building on strong market momentum, and as we look to 2026, we're poised to scale our DTC efforts even further to reach more people seeking clearer near vision."
Each Starter Pack includes 10 vials providing two daily doses for five days of treatment, accompanied by a patient progress tracker and referral card shipped directly to prescribing eye care professionals. Eye care professionals can request these packs through their Account Manager or by visiting Orasis.MySampleCloset.com.
Clinical Differentiation and Formulation
Qlosi (搜索) represents the only FDA-approved eye drop with the lowest effective concentration of pilocarpine for presbyopia (搜索) treatment. The product's proprietary EyeQ Formulation is designed for comfort and to maintain optimal pupil size, strengthening depth of focus and improving near vision without compromising mean distance or night vision.
The preservative-free formulation includes dual lubricating agents—hyaluronic acid and hydroxypropyl methylcellulose—delivered at a near-neutral pH for enhanced safety and patient comfort. Patients can use a single drop per eye for improved near vision for specific occasions or up to two drops daily for an extended effect lasting up to eight hours.
Clinical Evidence and Safety Profile
Qlosi (搜索)'s FDA approval in October 2023 was based on results from two pivotal Phase 3 clinical trials, NEAR-1 and NEAR-2, which evaluated efficacy, safety, and tolerability in more than 600 adult patients with presbyopia (搜索). The trials demonstrated a favorable safety profile with no serious side effects reported.
The most commonly reported treatment-related adverse events were headache and instillation site pain, occurring at rates of 6.8% and 5.8%, respectively. The mechanism of action involves pupil modulation, creating a "pinhole effect" that increases depth of field and enhances the ability to focus on near objects.
Clinical Perspective
"Many patients are surprised to learn that presbyopia (搜索) can be treated with an eye drop. Qlosi (搜索) has transformed these conversations, offering a flexible, comfortable option to improve near vision in appropriate patients," said Paul Karpecki, OD, FAAO, Director of Cornea and External Disease at Kentucky Eye Institute (搜索) and Associate Professor at University of Pikeville (搜索), Kentucky College of Optometry. "The feedback from my patients who have tried Qlosi has been outstanding, and with the Starter Packs, I now have an easy way to get them started on a new way of managing their presbyopia."
Market Context
Presbyopia (搜索) affects almost two billion people globally and more than 128 million people in the United States. The condition involves the loss of ability to focus on near objects due to natural aging, typically occurring after age 40 when the crystalline lens gradually stiffens and loses flexibility. The condition cannot be prevented or reversed and continues to progress gradually, creating significant unmet medical needs as existing treatment options can be either cumbersome or invasive.